Although the immune checkpoint inhibitors (ICIs) have demonstrated remarkable anti-tumor efficacy in solid tumors, the proportion of ESCC patients who benefit from ICIs remains limited. Current biomarkers have assisted in identifying potential respon...
BACKGROUND: Immune checkpoint inhibitors (CPIs) have revolutionized cancer therapy for several tumor indications. However, a substantial fraction of patients treated with CPIs derive no benefit or have short-lived responses to CPI therapy. Identifyin...
PURPOSE: Primary barriers to application of immune checkpoint inhibitor (ICI) therapy for cancer include severe side effects (such as potentially life threatening pneumonitis [PN]), which can cause the discontinuation of treatment. Predicting which p...
Cancer imaging : the official publication of the International Cancer Imaging Society
Feb 16, 2025
BACKGROUND: Immunotherapy has revolutionized the treatment landscape for head and neck squamous cell carcinoma (HNSCC) and PD-L1 combined positivity score (CPS) scoring is recommended as a biomarker for immunotherapy. Therefore, this study aimed to d...
BACKGROUND: Immune checkpoint inhibitors have proven efficacy against hepatitis B-virus positive hepatocellular. However, Immunotherapy-related adverse reactions are still a major challenge faced by tumor immunotherapy, so it is urgent to establish n...
Gastroenterology clinics of North America
Jan 24, 2025
Bacteria are associated with certain cancers and may induce genetic instability and cancer progression. The gut microbiome modulates the response to cancer therapy. Training machine learning models with response associated taxa or bacterial genes pre...
OBJECTIVE: To develop and validate a computed tomography (CT)-based deep learning radiomics model to predict treatment response and progression-free survival (PFS) in patients with unresectable hepatocellular carcinoma (uHCC) treated with transarteri...
Immunotherapy, especially immune checkpoint inhibitor (ICI) therapy, has yielded remarkable outcomes for some patients with solid cancers, but others do not respond to these treatments. Recent research has identified the gut microbiota as a key modul...
PURPOSE: Immune checkpoint inhibitors (ICIs) have demonstrated promise in the treatment of various cancers. Single-drug ICI therapy (immuno-oncology [IO] monotherapy) that targets PD-L1 is the standard of care in patients with advanced non-small cell...
Join thousands of healthcare professionals staying informed about the latest AI breakthroughs in medicine. Get curated insights delivered to your inbox.